Literature DB >> 1997399

Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major.

D M Yang1, M V Rogers, F Y Liew.   

Abstract

By using a series of overlapping synthetic peptides that cover more than 75% of the amino acid sequence of the major surface glycoprotein (gp63) from Leishmania major, 11 T-cell epitopes in CBA and BALB/c mice have been identified. Six of the peptides were recognized by T cells of CBA mice recovered from L. major infection, while one was recognized by the T cells from BALB/c mice recovered from the infection following sublethal doses of gamma-irradiation. Lymph node cells from mice immunized with the peptides also responded to a number of the same peptides (seven in CBA and one in BALB/c). Peptide p10-28 induced proliferative T-cell responses in both CBA and BALB/c mice. Five of the peptides (p10-28, p22-40, p289-309, p459-471 and p467-482) induced vigorous T-cell response in CBA mice but were not recognized by T cells from recovered mice. Four other peptides (p321-336, p364-476, p372-385 and p378-396) were recognized by T cells from recovered CBA mice but could not induce a T-cell response in normal CBA mice. Three peptides (p146-171, p289-309 and p395-414) were both able to induce a T-cell response and were recognized by T cells from recovered mice. However, only two peptides (p146-171 and p467-482) were able to activate T cells, which also recognized epitopes expressed by antigen-presenting cells infected with promastigotes. T cells induced by p146-171 and p467-171 or a mixture of these two peptides were mainly CD4+ and produced interleukin (IL-2) and interferon-gamma (IFN-gamma) but not IL-4 upon antigen stimulation in vitro. These two peptides also induced a classical delayed type hypersensitivity (DTH) response in CBA mice. Furthermore, CBA mice immunized with a mixture of the two peptides in Coryne parvum or entrapped in liposomes induced significant resistance against L. major infection. The implications of these results in terms of a synthetic vaccine against leishmaniasis and the mechanism of the induction of Th1 and Th2 cells are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1997399      PMCID: PMC1384327     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  The promastigote surface protease of Leishmania.

Authors:  C Bordier
Journal:  Parasitol Today       Date:  1987-05

2.  Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.

Authors:  L P Kahl; C A Scott; R Lelchuk; G Gregoriadis; F Y Liew
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

3.  Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo.

Authors:  S P Cobbold; A Jayasuriya; A Nash; T D Prospero; H Waldmann
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

4.  Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility.

Authors:  G F Mitchell; E Handman
Journal:  Aust J Exp Biol Med Sci       Date:  1983-02

5.  Prophylactic immunization against experimental leishmaniasis: I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection.

Authors:  J G Howard; S Nicklin; C Hale; F Y Liew
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

6.  A radioattenuated Leishmania major vaccine markedly increases the resistance of CBA mice to subsequent infection with Leishmania mexicana mexicana.

Authors:  J Alexander
Journal:  Trans R Soc Trop Med Hyg       Date:  1982       Impact factor: 2.184

7.  Leishmania gp63 molecule implicated in cellular adhesion lacks an Arg-Gly-Asp sequence.

Authors:  R A Miller; S G Reed; M Parsons
Journal:  Mol Biochem Parasitol       Date:  1990-03       Impact factor: 1.759

8.  Molecular cloning of the major surface antigen of leishmania.

Authors:  L L Button; W R McMaster
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

9.  Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.

Authors:  P Scott; P Natovitz; R L Coffman; E Pearce; A Sher
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  21 in total

1.  The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.

Authors:  Harshita Satija Grover; Nicolas Blanchard; Federico Gonzalez; Shiao Chan; Ellen A Robey; Nilabh Shastri
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

2.  Mapping T-cell epitopes in group A streptococcal type 5 M protein.

Authors:  J H Robinson; M C Atherton; J A Goodacre; M Pinkney; H Weightman; M A Kehoe
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

3.  Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Authors:  Mona E E Elfaki; Eltahir A G Khalil; Anne S De Groot; Ahmed M Musa; Andres Gutierrez; Brima M Younis; Kawthar A M Salih; Ahmed M El-Hassan
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

4.  Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.

Authors:  Javier Cote-Sierra; Amin Bredan; Carmen M Toldos; Benoit Stijlemans; Lea Brys; Pierre Cornelis; Manuel Segovia; Patrick de Baetselier; Hilde Revets
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Biochemical and biological characterization of the protective Leishmania pifanoi amastigote antigen P-8.

Authors:  M Colmenares; M Tiemeyer; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Authors:  E Handman; F M Symons; T M Baldwin; J M Curtis; J P Scheerlinck
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

8.  Human T-cell activation by 14- and 18-kilodalton nuclear proteins of Leishmania infantum.

Authors:  I Suffia; J F Quaranta; M C Eulalio; B Ferrua; P Marty; Y Le Fichoux; J Kubar
Journal:  Infect Immun       Date:  1995-10       Impact factor: 3.441

9.  A delayed-type hypersensitivity-inducing T-cell epitope of Semliki Forest virus mediates effective T-helper activity for antibody production.

Authors:  A Snijders; B J Benaissa-Trouw; H J Visser-Vernooy; I Fernandez; H Snippe; C A Kraaijeveld
Journal:  Immunology       Date:  1992-11       Impact factor: 7.397

10.  Immunogenicity and efficacy of single antigen Gp63, polytope and polytopeHSP70 DNA vaccines against visceral Leishmaniasis in experimental mouse model.

Authors:  Rakhee Sachdeva; Akhil C Banerjea; Nancy Malla; Mohan Lal Dubey
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.